3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
21
Nasopharyngeal Carcinoma
7
Colorectal Neoplasms
4
Breast Neoplasms
4
Nasopharyngeal Neoplasms
3
Lung Neoplasms
3
Uterine Cervical Neoplasms
2
Unspecified Adult Solid Tumor, Protocol Specific
2
Sarcoma
2
Recurrence
2
Neoplasms
2
Head and Neck Neoplasms
2
Unresectable Non-small Cell Lung Cancer
1
Squamous Non-small Cell Lung Cancer
1
Squamous Non-Small Cell Lung Cancer SqNSCLC
1
Solid Tumors
1
Optic Nerve Glioma
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neuroblastoma
1
Meningeal Carcinomatosis
1
Melanoma
1
Lymphoma, T-Cell
1
Locally Advanced Squamous Non-small Cell Lung Cancer
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Carcinoma, Hepatocellular
1
Advanced Pancreatic Cancer
1
Interventions
Bevacizumab
5
Everolimus
4
Sirolimus
2
Lapatinib
2
HDAC-42
2
vistusertib
1
temsirolimus
1
neratinib
1
icotinib
1
emvododstat
1
brolucizumab
1
brigatinib
1
aflibercept
1
Vascular Endothelial Growth Factor A
1
Valproic Acid
1
Sunitinib
1
Magnetic Resonance Imaging
1
Immunoglobulin G
1
Endostatins
1
Doxycycline
1
Disulfides
1
Crizotinib
1
Cetuximab
1
Axitinib
1
Aspirin
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neurofibromatosis 2
×
Endostatins
×
Clear all
NCT02104323
2017-02-09
Endostatin
Beijing Tiantan Hospital
Phase 2
Completed
20 enrolled